Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer
 

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

More...